NTLA Intellia Therapeutics, Inc. Stock Quote

NTLA [NASD]

Index	-	P/E	-	EPS (ttm)	-2.28	Insider Own	1.40%	Shs Outstand	61.29M	Perf Week	-16.46%
Market Cap	3.40B	Forward P/E	-	EPS next Y	-3.23	Insider Trans	-42.58%	Shs Float	52.88M	Perf Month	4.04%
Income	-120.30M	PEG	-	EPS next Q	-0.69	Inst Own	94.30%	Short Float	16.21%	Perf Quarter	73.69%
Sales	62.30M	P/S	54.50	EPS this Y	-13.80%	Inst Trans	9.30%	Short Ratio	4.85	Perf Half Y	191.37%
Book/sh	8.60	P/B	7.03	EPS next Y	-9.30%	ROA	-27.70%	Target Price	74.58	Perf Year	420.76%
Cash/sh	10.64	P/C	5.68	EPS next 5Y	30.00%	ROE	-36.90%	52W Range	9.18 - 92.00	Perf YTD	11.14%
Dividend	-	P/FCF	-	EPS past 5Y	-46.70%	ROI	-	52W High	-34.28%	Beta	2.02
Dividend %	-	Quick Ratio	9.60	Sales past 5Y	57.20%	Gross Margin	-	52W Low	558.61%	ATR	6.49
Employees	312	Current Ratio	9.60	Sales Q/Q	-39.40%	Oper. Margin	-	RSI (14)	42.74	Volatility	13.18% 8.96%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-20.10%	Profit Margin	-	Rel Volume	1.35	Prev Close	57.47
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Feb 25 BMO	Payout	-	Avg Volume	1.77M	Price	60.46
Recom	2.20	SMA20	-10.17%	SMA50	-9.15%	SMA200	74.39%	Volume	2,382,303	Change	5.20%

Dec-22-20

Downgrade

Robert W. Baird

Outperform → Neutral

$60

Oct-27-20

Initiated

Truist

Buy

$40

Oct-14-20

Initiated

Wells Fargo

Overweight

Sep-18-20

Initiated

Goldman

Buy

$33

Feb-28-20

Upgrade

Oppenheimer

Perform → Outperform

Feb-14-20

Downgrade

Wedbush

Outperform → Neutral

$16

Nov-01-19

Upgrade

Raymond James

Mkt Perform → Outperform

Jul-09-19

Initiated

Robert W. Baird

Outperform

$23

Jun-10-19

Initiated

ROTH Capital

Neutral

$16

May-03-19

Upgrade

Wedbush

Neutral → Outperform

$20 → $21

Apr-12-19

Initiated

Evercore ISI

Outperform

Nov-02-18

Downgrade

Wedbush

Outperform → Neutral

$36 → $20

Oct-29-18

Initiated

Credit Suisse

Neutral

$24

Sep-21-18

Initiated

Raymond James

Mkt Perform

May-15-18

Upgrade

Chardan Capital Markets

Neutral → Buy

$20 → $57.50

Mar-08-18

Initiated

JMP Securities

Mkt Outperform

$76

Nov-01-17

Reiterated

Jefferies

Buy

$36 → $42

Jun-22-17

Resumed

Jefferies

Buy

$36

Mar-28-17

Initiated

Chardan Capital Markets

Buy

$19

Aug-05-16

Upgrade

Jefferies

Hold → Buy

Feb-27-21 09:23AM	15 Fastest Growing Biotech Companies in the US Insider Monkey
Feb-26-21 12:59AM	Intellia (NTLA) Miss Earnings & Revenues Estimates in Q4 Zacks +5.20%
Feb-25-21 09:30PM	Intellia Therapeutics, Inc. (NTLA) Q4 2020 Earnings Call Transcript Motley Fool -9.81%
07:30AM	Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results GlobeNewswire
05:45AM	Intellia Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-18-21 07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2020 Earnings and Company Updates GlobeNewswire
Jan-29-21 09:44AM	A Highly Specialized Gene Editing Stock with a Clear Pathway to Big Gains InvestorPlace
Jan-20-21 08:23AM	The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics Zacks
Jan-15-21 06:12PM	7 CRISPR Stocks for the Future of Medicine InvestorPlace
Jan-14-21 03:11PM	With Rare Speed, Gene Editing Emerges as Biotechs New Cutting Edge Barrons.com +9.59%
Jan-11-21 08:02AM	The Zacks Analyst Blog Highlights: Intellia Therapeutics, Editas Medicine, Fate Therapeutic, CRISPR Therapeutics and Vertex Pharmaceuticals Zacks -7.12%
Jan-08-21 09:01AM	CRISPR Gene Editing Stocks Up After Intellia's Pipeline Update Zacks
Jan-07-21 04:24PM	Genetics Stocks Pop After Intellia Offers Update For Gene-Editing Drugs Investor's Business Daily +16.09%
01:05PM	Why Intellia Therapeutics Stock Is Soaring Today Motley Fool
08:42AM	3 Biotech Technological Developments to Watch Out For in 2021 Zacks
07:30AM	Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021 GlobeNewswire
Jan-06-21 11:00AM	A New Gene-Editing Technique May Be Able to Help Children Who Prematurely Age Barrons.com +9.39%
Jan-04-21 09:27AM	5 Disruptive Biotech Stocks With Solid Long-Term Potential Zacks
Jan-01-21 01:22AM	Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Could Be 41% Below Their Intrinsic Value Estimate Simply Wall St.
Dec-30-20 10:42AM	The Zacks Analyst Blog Highlights: Moderna, Ultragenyx Pharma, Fate Therapeutics, Intellia Therapeutics, and Mersana Therapeutics Zacks
Dec-29-20 12:27PM	Why CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics Stocks Are Sinking Today Motley Fool -10.27%
09:37AM	5 Biotech Stocks That Have Gained More Than 200% in 2020 Zacks
Dec-21-20 04:24PM	Genetics Stocks Ablaze: Editas, Crispr, Intellia Rocket; Uniqure Dives Investor's Business Daily +13.21%
Dec-16-20 09:33PM	Is NTLA A Good Stock To Buy Now? Insider Monkey
Dec-12-20 09:00AM	Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT Deficiency GlobeNewswire
Dec-10-20 02:03PM	CRISPR Gene Editing: Owning the Future of Medicine Zacks +14.68%
Dec-09-20 11:06AM	Gene-Editing Stocks Skyrocket in $1.6 Billion Boom After Data Bloomberg
Dec-07-20 04:20PM	Here Are The Winners Of This Year's Biggest Blood Cancer Meeting Investor's Business Daily +7.25%
Dec-05-20 10:00AM	Intellia Therapeutics Presents New Preclinical Data Supporting Its CRISPR/Cas9-Engineered TCR-T Cell Treatment for Acute Myeloid Leukemia at the 62nd ASH Annual Meeting GlobeNewswire
Dec-04-20 04:01PM	Intellia Therapeutics Announces Closing of $201 Million Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
08:00AM	New Results on Blood Disorder Treatments Are Coming. Watch These Stocks. Barrons.com
Dec-03-20 08:41AM	Intellia (NTLA) Catches Eye: Stock Jumps 7.8% Zacks
Dec-01-20 09:30PM	Intellia Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
Nov-30-20 04:01PM	Intellia Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Nov-11-20 07:30AM	Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments GlobeNewswire
Nov-09-20 07:30AM	Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis GlobeNewswire
05:57AM	Analysts Have Lowered Expectations For Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its Latest Results Simply Wall St.
Nov-06-20 05:30PM	Intellia Therapeutics, Inc. (NTLA) Q3 2020 Earnings Call Transcript Motley Fool
Nov-05-20 07:30AM	Intellia Therapeutics Announces Third Quarter 2020 Financial Results GlobeNewswire
06:15AM	Intellia Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Oct-29-20 07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2020 Earnings and Company Updates GlobeNewswire
Oct-27-20 10:35AM	Benzinga's Top Upgrades, Downgrades For October 27, 2020 Benzinga
Oct-19-20 07:30AM	Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR) GlobeNewswire
Oct-07-20 04:20PM	Intellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the Revolutionary CRISPR/Cas9 Genome Editing Technology GlobeNewswire +13.18%
10:04AM	Nobel Prize for Gene-Editing Innovators Boosts Crispr Therapeutics and Other Stocks Barrons.com
Oct-05-20 07:30AM	Intellia Therapeutics Names John F. Crowley to Board of Directors GlobeNewswire +10.30%
Sep-29-20 08:20AM	Intellia Therapeutics Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based Treatment GlobeNewswire
Sep-28-20 08:00AM	Intellia Therapeutics to Present at Chardans Virtual 4th Annual Genetic Medicines Conference GlobeNewswire
Sep-22-20 09:43AM	Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 50% TipRanks
Sep-18-20 09:31AM	Benzinga's Top Upgrades, Downgrades For September 18, 2020 Benzinga
Sep-02-20 08:00AM	Intellia Therapeutics to Present at Bairds 2020 Virtual Global Healthcare Conference GlobeNewswire
Aug-11-20 11:10AM	We're Not Worried About Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Simply Wall St.
11:06AM	How Much Of Intellia Therapeutics, Inc. (NASDAQ:NTLA) Do Institutions Own? Simply Wall St.
Aug-06-20 09:15AM	Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates Zacks
07:30AM	Intellia Therapeutics Announces Second Quarter 2020 Financial Results GlobeNewswire
Aug-03-20 08:00AM	Intellia Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference GlobeNewswire +8.09%
Jul-30-20 12:33PM	Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q2 Earnings Expected to Decline Zacks
07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2020 Earnings and Company Updates GlobeNewswire
Jul-25-20 11:52AM	Gene Therapy Companies Are Racing to Cure Sickle Cell. That Would Open the Door to Curing Dozens of Other Diseases. Barrons.com
Jul-14-20 07:07AM	Is Intellia Therapeutics Stock a Buy? Motley Fool
Jul-05-20 10:52PM	Intellia Therapeutics, Inc. (NTLA): Hedge Funds Taking Some Chips Off The Table Insider Monkey
Jul-02-20 11:32AM	Better Buy: Editas Medicine vs. Intellia Motley Fool
Jun-10-20 11:48PM	Edited Transcript of NTLA earnings conference call or presentation 7-May-20 12:00pm GMT Thomson Reuters StreetEvents
Jun-05-20 04:01PM	Intellia Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
12:37AM	Intellia Therapeutics (NTLA) Catches Eye: Stock Jumps 10.2% Zacks
Jun-03-20 09:56AM	Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More Zacks +10.22%
07:54AM	Better Buy: CRISPR Therapeutics vs. Intellia Motley Fool
07:02AM	Why Editas Medicine Is Now the CRISPR Stock to Really Watch Motley Fool
Jun-02-20 09:00PM	Intellia Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
11:09AM	Regeneron Expands Deal With Intellia for Hemophilia Treatments Zacks
09:15AM	Stocks Still Rising to Begin June Zacks
07:45AM	The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs Benzinga
02:35AM	Regeneron, Intellia Expand Partnership To Develop Hemophilia Treatments SmarterAnalyst
Jun-01-20 04:00PM	Intellia Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire +19.47%
11:46AM	Here's Why Intellia Therapeutics Gained as Much as 18.0% Today Motley Fool
07:57AM	Regeneron to expand development deal with Intellia Therapeutics MarketWatch
07:00AM	Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments PR Newswire
May-22-20 07:39AM	Here's Why Editas Could Beat Intellia to a CRISPR Therapy Motley Fool
May-18-20 07:12PM	Intellia Therapeutics Sees Relative Strength Rating Rise To 92 Amid Cancer Treatment Development Investor's Business Daily +5.89%
May-12-20 06:00AM	Intellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy GlobeNewswire
May-11-20 07:43AM	Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report Simply Wall St. +14.30%
May-09-20 01:31PM	Intellia Therapeutics, Inc. (NTLA) Q1 2020 Earnings Call Transcript Motley Fool
May-07-20 09:15AM	Intellia Therapeutics Inc (NTLA) Reports Q1 Loss, Misses Revenue Estimates Zacks
08:38AM	Recap: Intellia Therapeutics Q1 Earnings Benzinga
07:30AM	Intellia Therapeutics Announces First Quarter 2020 Financial Results GlobeNewswire
Apr-30-20 12:34PM	Will Intellia Therapeutics, Inc. (NTLA) Report Negative Q1 Earnings? What You Should Know Zacks -6.00%
07:50AM	Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer GlobeNewswire
07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2020 Earnings and Company Updates GlobeNewswire
Apr-28-20 04:30PM	Intellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy GlobeNewswire -7.81%
Apr-13-20 12:00PM	How Does Intellia Therapeutics, Inc. (NASDAQ:NTLA) Affect Your Portfolio Volatility? Simply Wall St.
Apr-06-20 06:26PM	Alnylam, Dicerna Join Forces to Take on Arrowhead GuruFocus.com +6.01%
Mar-31-20 07:30AM	FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics GlobeNewswire
Mar-24-20 04:19PM	Edited Transcript of NTLA earnings conference call or presentation 27-Feb-20 1:00pm GMT Thomson Reuters StreetEvents
Feb-27-20 08:55AM	Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates Zacks -5.57%
07:30AM	Intellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results GlobeNewswire
Feb-20-20 10:53AM	Intellia (NTLA) to Report Q4 Earnings: What's in Store? Zacks
07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2019 Earnings and Company Update GlobeNewswire
Feb-19-20 12:31PM	Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q4 Earnings Expected to Decline Zacks
Feb-12-20 09:33AM	Here's Why We're Not Too Worried About Intellia Therapeutics's (NASDAQ:NTLA) Cash Burn Situation Simply Wall St.
Feb-10-20 07:30AM	Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposias Engineering the Genome Conference GlobeNewswire +9.40%

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company develops in vivo programs focusing on liver diseases, including transthyretin amyloidosis and hereditary angioedema, as well as other research programs comprising primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; Ospedale San Raffaele; and GEMoaB Monoconals GmbH. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LEONARD JOHN M	President and CEO	Feb 09	Option Exercise	6.83	56,718	387,384	688,579	Feb 09 08:36 PM
Rivera Jose E	EVP, General Counsel	Feb 09	Option Exercise	18.30	21,000	384,195	129,409	Feb 09 08:38 PM
Rivera Jose E	EVP, General Counsel	Feb 09	Sale	75.00	11,489	861,675	117,920	Feb 09 08:38 PM
LEONARD JOHN M	President and CEO	Feb 09	Sale	75.00	28,043	2,103,225	660,536	Feb 09 08:36 PM
LEONARD JOHN M	President and CEO	Feb 05	Option Exercise	13.40	40,000	536,000	654,803	Feb 09 08:36 PM
LEONARD JOHN M	President and CEO	Feb 05	Sale	67.66	22,942	1,552,185	631,861	Feb 09 08:36 PM
LEONARD JOHN M	President and CEO	Feb 03	Option Exercise	17.68	117,060	2,069,793	651,661	Feb 03 09:39 PM
LEONARD JOHN M	President and CEO	Feb 03	Sale	72.54	67,856	4,922,490	584,601	Feb 03 09:39 PM
Rivera Jose E	EVP, General Counsel	Feb 01	Option Exercise	9.68	109,000	1,054,620	121,686	Feb 03 09:38 PM
LEONARD JOHN M	President and CEO	Feb 01	Option Exercise	13.69	200,000	2,737,600	598,814	Feb 03 09:39 PM
LEONARD JOHN M	President and CEO	Feb 01	Sale	64.00	109,889	7,032,905	523,853	Feb 03 09:39 PM
Rivera Jose E	EVP, General Counsel	Feb 01	Sale	63.99	54,659	3,497,902	88,686	Feb 03 09:38 PM
Cohen Fred E	Director	Jan 20	Option Exercise	13.78	20,000	275,600	30,000	Jan 22 04:22 PM
LEONARD JOHN M	President and CEO	Jan 05	Sale	55.86	6,239	348,511	475,488	Jan 05 09:24 PM
SCHIERMEIER ANDREW	EVP, Chief Operating Officer	Jan 05	Sale	55.86	1,377	76,919	16,656	Jan 05 08:58 PM
Rivera Jose E	EVP, General Counsel	Jan 05	Sale	55.86	2,078	116,077	51,990	Jan 05 08:55 PM
LEONARD JOHN M	President and CEO	Dec 31	Option Exercise	0.00	14,375	0	481,727	Jan 05 09:24 PM
SCHIERMEIER ANDREW	EVP, Chief Operating Officer	Dec 31	Option Exercise	0.00	4,792	0	18,033	Jan 05 08:58 PM
Rivera Jose E	EVP, General Counsel	Dec 31	Option Exercise	0.00	4,792	0	54,068	Jan 05 08:55 PM
SCHIERMEIER ANDREW	EVP, Chief Operating Officer	Dec 30	Option Exercise	13.48	1,500	20,220	12,673	Jan 04 09:03 PM
KARSEN PERRY A	Director	Dec 17	Option Exercise	18.45	88,764	1,637,842	93,764	Dec 18 04:29 PM
KARSEN PERRY A	Director	Dec 17	Sale	53.55	88,764	4,753,680	5,000	Dec 18 04:29 PM
Rivera Jose E	EVP, General Counsel	Dec 01	Option Exercise	13.88	5,000	69,400	52,072	Dec 03 06:42 PM
Rivera Jose E	EVP, General Counsel	Dec 01	Sale	38.21	3,364	128,525	48,708	Dec 03 06:42 PM
LEONARD JOHN M	President and CEO	Nov 27	Option Exercise	16.17	35,000	566,100	487,352	Nov 27 09:00 PM
LEONARD JOHN M	President and CEO	Nov 27	Sale	38.57	35,000	1,350,000	467,352	Nov 27 09:00 PM
LEONARD JOHN M	President and CEO	Nov 25	Option Exercise	6.83	50,000	341,500	517,352	Nov 25 08:02 PM
LEONARD JOHN M	President and CEO	Nov 25	Sale	36.00	50,000	1,800,000	467,352	Nov 25 08:02 PM
Rivera Jose E	EVP, General Counsel	Nov 18	Option Exercise	18.30	848	15,518	47,696	Nov 18 07:55 PM
Rivera Jose E	EVP, General Counsel	Nov 18	Sale	35.00	624	21,840	47,072	Nov 18 07:55 PM
Rivera Jose E	EVP, General Counsel	Nov 16	Option Exercise	7.44	10,562	78,585	52,315	Nov 18 07:55 PM
LEONARD JOHN M	President and CEO	Nov 16	Option Exercise	14.58	20,000	291,600	487,352	Nov 18 07:56 PM
LEONARD JOHN M	President and CEO	Nov 16	Sale	34.00	20,000	680,000	467,352	Nov 18 07:56 PM
Rivera Jose E	EVP, General Counsel	Nov 16	Sale	34.29	6,029	206,728	46,700	Nov 18 07:55 PM
LEONARD JOHN M	President and CEO	Nov 04	Option Exercise	6.83	50,000	341,500	517,352	Nov 06 04:38 PM
Rivera Jose E	EVP, General Counsel	Nov 04	Option Exercise	13.88	5,000	69,400	45,679	Nov 06 04:41 PM
Rivera Jose E	EVP, General Counsel	Nov 04	Sale	28.00	3,364	94,192	42,315	Nov 06 04:41 PM
LEONARD JOHN M	President and CEO	Nov 04	Sale	26.00	50,000	1,300,000	467,352	Nov 06 04:38 PM
Rivera Jose E	EVP, General Counsel	Oct 15	Option Exercise	6.83	10,000	68,300	46,294	Oct 16 08:58 PM
Rivera Jose E	EVP, General Counsel	Oct 15	Sale	24.20	5,615	135,883	40,679	Oct 16 08:58 PM
LEONARD JOHN M	President and CEO	Oct 07	Option Exercise	6.83	5,000	34,150	472,352	Oct 09 04:14 PM
LEONARD JOHN M	President and CEO	Oct 07	Sale	21.83	5,000	109,150	467,352	Oct 09 04:14 PM
Rivera Jose E	EVP, General Counsel	Sep 15	Option Exercise	6.83	10,000	68,300	41,909	Sep 17 04:55 PM
Rivera Jose E	EVP, General Counsel	Sep 15	Sale	21.04	5,615	118,140	36,294	Sep 17 04:55 PM
LEONARD JOHN M.	President and CEO	Sep 01	Option Exercise	6.83	5,000	34,150	472,352	Sep 03 04:15 PM
LEONARD JOHN M.	President and CEO	Sep 01	Sale	21.83	5,000	109,150	467,352	Sep 03 04:15 PM
Rivera Jose E	EVP, General Counsel	Aug 18	Option Exercise	6.83	10,000	68,300	37,524	Aug 20 04:13 PM
Rivera Jose E	EVP, General Counsel	Aug 18	Sale	21.00	5,615	117,915	31,909	Aug 20 04:13 PM
LEONARD JOHN M.	President and CEO	Aug 06	Option Exercise	6.83	5,000	34,150	472,352	Aug 07 07:29 PM
LEONARD JOHN M.	President and CEO	Aug 06	Sale	21.83	5,000	109,150	467,352	Aug 07 07:29 PM
Rivera Jose E	EVP, General Counsel	Jul 15	Option Exercise	6.83	10,000	68,300	33,139	Jul 17 04:18 PM
Rivera Jose E	EVP, General Counsel	Jul 15	Sale	22.70	5,615	127,461	27,524	Jul 17 04:18 PM
LEONARD JOHN M.	President and CEO	Jul 01	Option Exercise	6.83	5,000	34,150	472,352	Jul 02 04:10 PM
LEONARD JOHN M.	President and CEO	Jul 01	Sale	21.83	5,000	109,150	467,352	Jul 02 04:10 PM
Rivera Jose E	EVP, General Counsel	Jun 16	Option Exercise	6.83	10,000	68,300	27,897	Jun 18 05:00 PM
Rivera Jose E	EVP, General Counsel	Jun 16	Sale	21.00	5,615	117,915	22,282	Jun 18 05:00 PM
LEONARD JOHN M.	President and CEO	Jun 03	Option Exercise	6.83	5,000	34,150	472,352	Jun 05 05:18 PM
LEONARD JOHN M.	President and CEO	Jun 03	Sale	21.83	5,000	109,150	467,352	Jun 05 05:18 PM
Rivera Jose E	EVP, General Counsel	May 26	Option Exercise	6.83	10,000	68,300	285,722	May 28 05:23 PM
Rivera Jose E	EVP, General Counsel	May 26	Sale	21.21	5,615	119,094	280,107	May 28 05:23 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience